Try our beta test site

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination With Epacadostat (INCB024360) in Subjects With Selected Cancers (INCB 24360-202 / MK-3475-037 / KEYNOTE-037/ ECHO-202)

This study is currently recruiting participants. (see Contacts and Locations)
Verified November 2016 by Incyte Corporation
Sponsor:
Collaborator:
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Incyte Corporation
ClinicalTrials.gov Identifier:
NCT02178722
First received: June 26, 2014
Last updated: November 9, 2016
Last verified: November 2016
  Purpose
The purpose of this study is to assess the safety, tolerability, and efficacy when combining MK-3475 and INCB024360 in subjects with certain cancers. This study will be conducted in 2 phases, Phase 1 and Phase 2.

Condition Intervention Phase
Malignant Solid Tumor
Lymphoma, Large B-Cell, Diffuse
Carcinoma, Non-Small-Cell Lung
Transitional Cell Carcinoma of Urinary Tract
Triple Negative Breast Cancer
Carcinoma, Squamous Cell of Head and Neck
Ovarian Neoplasms
Adenocarcinoma of the Endometrium
Renal Cell Carcinoma
Microsatellite-instability (MSI) High Colorectal Cancer
Drug: MK-3475
Drug: INCB024360
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination With Epacadostat (INCB024360) in Subjects With Selected Cancers (KEYNOTE-037/ ECHO-202)

Resource links provided by NLM:


Further study details as provided by Incyte Corporation:

Primary Outcome Measures:
  • Phase 1: Number of subjects with dose limiting toxicities (DLTs) of INCB024360 in combination with MK-3475 [ Time Frame: 56 days ]
  • Phase 2: Objective response rate [ Time Frame: Assessed every 9 weeks for duration of study participation which is estimated to be 18 months ]

Secondary Outcome Measures:
  • Progression free survival [ Time Frame: Response is measured every 9 weeks for duration of study participation which is estimated to be 18 months ]
  • Number of subjects with Adverse Events as a Measure of Safety and Tolerability of INCB024360 in combination with MK-3475 [ Time Frame: Adverse events are assessed every 3 weeks for duration of study participation which is estimated to be 18 months ]
  • Overall survival (OS) [ Time Frame: Patients are checked for survival every 12 weeks for duration of study participation which is estimated to be 18 months ]

Estimated Enrollment: 403
Study Start Date: June 2014
Estimated Study Completion Date: November 2017
Estimated Primary Completion Date: May 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Phase 1: MK-3475 + INCB024360
Phase 1: MK-3475 + INCB024360 25 mg BID as starting dose, followed by dose escalations (Phase 1) until recommended phase 2 dose of INCB024360 is determined
Drug: MK-3475
IV infusion
Drug: INCB024360
Oral daily dosing
Experimental: Phase 2: MK-3475 + INCB024360
(recommended phase 2 dose)
Drug: MK-3475
IV infusion
Drug: INCB024360
Oral daily dosing

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subjects with histologically or cytologically NSCLC, melanoma, transitional cell carcinoma of the GU tract, renal cell cancer, triple negative breast cancer, adenocarcinoma of the endometrium or squamous cell carcinoma of the head and neck (Phase 1)
  • Subjects with histologically confirmed melanoma, NSCLC, transitional cell carcinoma of the GU tract, TNBC, SCCHN, ovarian cancer, MSI high CRC, RCC and DLBCL (Phase 2)
  • Life expectancy > 12 weeks.
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 - 1.
  • Presence of measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 or Lugano Classification for subjects with DLBCL.
  • Laboratory and medical history parameters within protocol-defined range.
  • For Phase 1: Subjects who have advanced or metastatic disease as noted above that have received at least one prior therapy or have advanced or metastatic disease for which no curative treatment is available may be enrolled.
  • For Phase 2 expansion cohorts: Subjects with NSCLC, melanoma, transitional cell carcinoma of the GU tract, SCCHN, ovarian cancer, MSI high CRC, RCC, DLBCL, and TNBC.

    • Phase 2 expansion: NSCLC

      • Subjects who have received at least 1 prior platinum-based therapy. Subjects who have a non-platinum-based regimen may be enrolled with medical monitor approval.
      • Tumors with epidermal growth factor receptor mutation positive or anaplastic lymphoma kinase fusion oncogene positive treated with a tyrosine kinase inhibitor are permitted; however, subjects should have progressed on or be intolerant to the targeted therapy.
      • Subjects must not have received immunotherapy with PD-1 or CTLA-4 targeted therapy.
    • Phase 2 expansion: Melanoma

      • Documentation of V600E-activating BRAF mutation status
      • Subjects must not have received immunotherapy with anti-PD-1, anti-PD-L1, or anti-CTLA-4 therapy. Exception: Prior anti−CTLA-4 in the adjuvant setting would be permitted.
      • Ocular melanoma is excluded.
    • Phase 2 expansion: Transitional cell carcinoma of the GU tract

      • Metastatic or locally advanced and not amenable to curative therapy with disease progression on or after platinum-based chemotherapy or alternative therapy if platinum-based therapy is not appropriate.
      • Prior PD-1 or CTLA-4 targeted therapies are excluded
    • Phase 2 expansion: SCCHN

      • Histologically confirmed metastatic or recurrent squamous cell carcinoma not amenable to local therapy with curative intent (surgery or radiation with or without chemotherapy). Carcinoma of the nasopharynx, salivary gland, or nonsquamous histologies are excluded.
      • Subjects must have received at least 1 prior systemic chemotherapy regimen that must have included a platinum-based therapy.
      • Prior PD-1 or CTLA-4 targeted therapies are excluded.
    • Phase 2 expansion: Ovarian cancer

      • Subjects with FIGO Stage Ic, Stage II, Stage III, Stage IV, recurrent, or persistent (unresectable) histologically confirmed epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube carcinoma.
      • Subjects must have received a platinum-taxane-based regimen as first-line therapy.
      • Prior PD-1 or CTLA-4 targeted therapies are excluded.
      • Borderline, low-malignant-potential epithelial carcinoma per histopathology is excluded.
    • Phase 2 expansion: Relapsed or refractory DLBCL

      • Prior allogeneic stem-cell transplantation is excluded.
      • Must have received > or = 1 prior treatment regimen.
      • Not a candidate for curative therapy or hematopoietic stem-cell transplantation (either due to disease burden, fitness, or preference).
      • Prior PD-1 or CTLA-4 targeted therapies are excluded.
    • Phase 2 expansion: TNBC

      • Histologically confirmed breast adenocarcinoma that is unresectable loco regional, or metastatic
      • Pathologically confirmed as triple negative, source documented, defined as both of the following:
      • Estrogen receptor (ER) and progesterone receptor (PgR) negative
      • Human epidermal growth factor receptor 2 (HER2) negative as per American Society of Clinical Oncology/College of American Pathologists guidelines
      • Subject must have received at least 1 prior systemic regimen for advanced or metastatic disease
      • Prior PD-1 or CTLA-4 targeted therapies are excluded.
    • Phase 2 expansion: RCC

      • Subjects with histological or cytological confirmation of clear cell RCC.
      • Not curable by surgery.
      • Subjects must have received prior antiangiogenic therapy
      • Subjects must not have received prior immunotherapy with anti-PD-1, anti-PD-L1, or anti-CTLA-4 therapy
    • Phase 2 expansion: MSI high CRC

      • Subjects with histological confirmation of locally advanced unresectable or metastatic MSI high CRC
      • MSI status is, respectively, determined by examining CRC tumor
    • Tumor biopsies are required. If a subject has inaccessible lesions, such as in ovarian cancer, or highly vascular lesions, such as RCC, enrollment may be considered with medical monitor approval, and archived tissue may be acceptable.
    • Females of child-bearing potential and males who use adequate birth control through 120 days post dose.

Exclusion Criteria:

• Subjects who participated in any other study in which receipt of an investigational study drug or device occurred within 28 days or 5 half-lives (whichever is longer) prior to first dose.

Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways). Exception: Prior anti−CTLA-4 in the adjuvant setting for subjects with melanoma would be permitted.

  • Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Subjects with previously treated brain metastases may participate provided they are stable.
  • Has an active autoimmune disease.
  • Has evidence of interstitial lung disease or pneumonitis.
  • Live vaccine use within 30 days of first dose of study medication
  • Monoamine oxidase inhibitors
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02178722

Contacts
Contact: Incyte Call Center 1-855-463-3463

  Show 24 Study Locations
Sponsors and Collaborators
Incyte Corporation
Merck Sharp & Dohme Corp.
Investigators
Study Director: Mark Jones, MD Incyte Corporation
  More Information

Responsible Party: Incyte Corporation
ClinicalTrials.gov Identifier: NCT02178722     History of Changes
Other Study ID Numbers: INCB 24360-202/ ECHO-202
Study First Received: June 26, 2014
Last Updated: November 9, 2016

Additional relevant MeSH terms:
Pembrolizumab
Carcinoma
Colorectal Neoplasms
Adenocarcinoma
Carcinoma, Renal Cell
Carcinoma, Non-Small-Cell Lung
Carcinoma, Transitional Cell
Triple Negative Breast Neoplasms
Ovarian Neoplasms
Carcinoma, Squamous Cell
Head and Neck Neoplasms
Lymphoma, Large B-Cell, Diffuse
Uterine Neoplasms
Microsatellite Instability
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Kidney Neoplasms
Urologic Neoplasms
Urogenital Neoplasms
Kidney Diseases

ClinicalTrials.gov processed this record on March 24, 2017